YARW (Yarrow Bioscience) Debt-to-Equity: 0.00 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

YARW Yarrow Bioscience Inc YARW
13 GF Score
Price $26.22
View Full Analysis

What is Yarrow Bioscience Debt-to-Equity?

Yarrow Bioscience YARW -2.78% 13 Debt-to-Equity is 0.00 as of Jun. 2026. GuruFocus rates YARW with a GF Score™ of 13/100. Among 966 Biotechnology companies, Yarrow Bioscience ranks worse than 103519.57% on this metric.

Yarrow Bioscience's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $0.00 Mil. Yarrow Bioscience's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was $0.00 Mil. Yarrow Bioscience's Total Stockholders Equity for the quarter that ended in Jun. 2026 was $22.06 Mil. Yarrow Bioscience's debt to equity for the quarter that ended in Jun. 2026 was 0.00.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Yarrow Bioscience's Debt-to-Equity or its related term are showing as below:

YARW's Debt-to-Equity is not ranked *
in the Biotechnology industry.
Industry Median: 0.15
* Ranked among companies with meaningful Debt-to-Equity only.

Yarrow Bioscience  (NAS:YARW) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Yarrow Bioscience Debt-to-Equity Related Terms

Yarrow Bioscience Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for Yarrow Bioscience's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Yarrow Bioscience Debt-to-Equity Chart

Yarrow Bioscience Annual Data
Trend Dec25
Debt-to-Equity
0.00

Yarrow Bioscience Quarterly Data
Jun25 Dec25 Mar26 Jun26
Debt-to-Equity N/A 0.00 0.00 0.00

YARW vs CGTX, RANI, VRCA: Debt-to-Equity Comparison

For the Biotechnology subindustry, Yarrow Bioscience's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Yarrow Bioscience Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Yarrow Bioscience's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Yarrow Bioscience's Debt-to-Equity falls into.


YARW
13GF Score
Yarrow Bioscience Inc YARW
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Yarrow Bioscience Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Yarrow Bioscience's Debt to Equity Ratio for the fiscal year that ended in Dec. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 28.86
=0.00

Yarrow Bioscience's Debt to Equity Ratio for the quarter that ended in Jun. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0 + 0) / 22.062
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 0.00 mean?
Yarrow Bioscience (YARW) has a Debt-to-Equity of 0.00 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Yarrow Bioscience and its competitors. According to the industry distribution chart, Yarrow Bioscience ranks #999999 out of 966 companies in the Biotechnology industry.
Is Yarrow Bioscience's Debt-to-Equity too high?
Yarrow Bioscience's current Debt-to-Equity is 0.00. Based on the distribution chart, Yarrow Bioscience ranks #999999 out of 966 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Yarrow Bioscience has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Yarrow Bioscience's Debt-to-Equity compare to CGTX and RANI?
According to the Biotechnology industry distribution chart, Yarrow Bioscience ranks #999999 out of 966 companies for Debt-to-Equity. This places Yarrow Bioscience in the lower half of its industry. The industry median Debt-to-Equity is 0.15. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.15, based on 966 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Yarrow Bioscience and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.15 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Yarrow Bioscience's current Debt-to-Equity is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Yarrow Bioscience stock overvalued right now?
Yarrow Bioscience (YARW) has a current Debt-to-Equity of 0.00. The current Debt-to-Equity is 0.00. Yarrow Bioscience's overall GF Score™ is 13/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Yarrow Bioscience (YARW), the current Debt-to-Equity is 0.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Yarrow Bioscience Business Description

Address 251 Little Falls Drive, County of New Castle, City of Wilmington, DE, USA, 19808
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.
13GF Score

Get the complete analysis for YARW

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.22
Price